Digital & Innovation
AI-powered platform to cut hospitalisation for diabetes patients
Digital & Innovation: Coinciding with National Diabetes Week (14-21 July), PenCS has launched an AI powered diabetes platform to proactively identify individuals at risk of diabetes, and better manage planned and preventive care for diabetes patients.
The Diabetes Quality (QI) Improvement Program includes AI risk stratification to determine the risk of an individual making an unplanned visit to a hospital over the next 12 months, can improve clinical outcomes and potentially increase gross billings by over $22,000 annually per GP for diabetes.
Edweana Wenkart, PenCS CEO, said “PenCS new platform is empowering General Practices and Aboriginal Member Services to expand beyond episodic care into value-based healthcare, aligned with MyMedicare CDM. Practice Cloud is having a measurable impact on our health system and improving financial sustainability for practices.”
In an interview with Health Industry Hub, Dr Kean-Seng Lim, Chief Medical Advisor of PenCS, said “This tool allows us to redefine how we approach healthcare by analysing whole-person data at a population level.
“By identifying high-risk patient cohorts, we can tailor interventions specific to their needs, whether it be medication adjustments, health coaching, or other forms of support.”
Dr Jaspreet Saini, GP and Clinic Director, Rosedale Medical Practice & Healthicare, commented “We use the risk stratification tool to understand risk and tailor intervention, provide continuous monitoring and follow up via run sheets, ensure a team-based care approach to engage the broader health team, and use predictive analytics. Our care plans include goals, a management team is structured, and we have a review every three months to make sure those goals are being realised.
She added, “We are very excited about how seamlessly the software provides data-driven insights to drive both clinical and financial outcomes in our practices. The tool’s alignment with Quality Improvement (QI) methodology, particularly Plan-Do-Study-Act (PDSA) cycles, is exceptional.”
The company’s digital health solutions are currently in 60% (3,800) of Australia’s medical practices.
In reimagining healthcare, Health Industry HubTM is the ONLY one-stop-hub uniting the diversity of Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change. The exclusive leadership and influencer podcasts and vodcasts offer unparalleled insights and add immense value to our breaking news coverage.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News & Trends - Pharmaceuticals
Lilly’s drug cuts diabetes risk by 94%, so why is it still not on the PBS?
On World Diabetes Day (14 November), new data reveals that three years of treatment with a GIP/GLP-1 receptor agonist significantly […]
MoreNews & Trends - Biotechnology
Depaz Oration to celebrate an ‘enduring’ legacy in the biotech sector
AusBiotech announced the establishment of the Depaz Oration, an annual keynote event that will debut at the AusBiotech Conference in […]
MoreNews & Trends - Pharmaceuticals
Government calls for public input on genomic-led cancer care
The Australian Government has launched a public consultation on a draft policy framework aimed at enhancing genomics-informed cancer care nationwide. […]
MoreNews & Trends - MedTech & Diagnostics
Can the patient voice reduce low-value care? Australia’s first large-scale hospital initiative seeks answers
In an Australian-first, a not-for-profit private health insurer will ask hospital patients to rate not only their clinical care but […]
More